Why the study?
What are the prognostic factors affecting overall and disease-free survival in patients with resected synovial sarcoma?
What are the prognostic factors affecting overall and disease-free survival in patients with resected synovial sarcoma?
In patients with resected synovial sarcoma, high mitotic activity is an independent adverse prognostic factor for disease-free survival.
May refine risk stratification after synovial sarcoma resection; hypothesis-generating pending prospective validation.
BACKGROUND: Synovial sarcoma (SS) is a rare disease and compared with other soft-tissue sarcomas has a relatively high mortality rate. The optimal management of this disease and prognostic factors associated with patient outcome remains controversial. AIMS: We aimed to evaluate the factors affecting the outcomes of SS patients in the adjuvant setting. PATIENTS AND METHODS: In this Turkish multicenter study, we assessed the data of 69 SS patients regarding prognostic factors for SS patients retrospectively. RESULTS: Our study included 69 localized SS patients (38 males and 31 females) with a median age of 34.5 years (minimum-maximum: 14-68 years). Overall survival (OS) and disease free survival (DFS) rates for 5 years were 64% and 25%, respectively. All patients under went surgical treatment; 64 patients were treated with a wide excision and 5 patients had an amputation. According to the univariate analysis, adverse prognostic factors for OS were male sex, higher mitotic activity, high Ki-67 levels, trunk localization and inadequate surgical margins. In multivariate analysis, none of these factors had independent significant association with OS. Prognostic factors for DFS; in the univariate analysis were higher mitotic activity, high Ki-67 levels and inadequate surgical margins. Only higher mitotic activity (≥10 high-power field) was significantly associated with worse DFS in the multivariate analysis (hazard ratio: 0.30, % confidence interval: 0.11-0.80, P = 0.017). CONCLUSION: Our study confirms that high mitotic activity is significantly associated with decreased DFS. The question of whether the chemotherapy provides a survival advantage in patients having adverse prognostic factors requires confirmation in randomized trials.
No takes yet. Share an insight, caveat, or question.
Yetişyiğit et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: